Skip to Main Content

Paper Details

Effect of pharmacological heart failure drugs and gene therapy on Danon's cardiomyopathy.
Biochem Pharmacol
0
2023
Angiotensin II, Danon disease, Danon's, Danon's cardiomyopathy, Heart failure, L2, L2 mice, LAMP2, LAMP2 cardiomyopathy, LAMP2 mutations, LAMP2-exon-6-deletion, Metoprolol, Mice, RAAS, Ramipril, Spironolactone, X-linked genetic disease, cardiac hypertrophy, cardiomyopathy, dilated cardiomyopathy, fibrosis, heart failure, human, hypertrophy, left ventricular hypertrophy, mice, mouse, neonates, patients, systolic dysfunction, troponin, ventricular dilatation
Author NameAffiliation
Jonathan G SeidmanHarvard Medical School
Jonathan G SeidmanHarvard Medical School
Christine E SeidmanHoward Hughes Medical Institute and Cardiovascular Division, Brigham and Women's Hospital
Christine E SeidmanHoward Hughes Medical Institute and Cardiovascular Division, Brigham and Women's Hospital
  • 1 - 4

Datasets

Release 1.2